Sponsor or institution
Clinical trials and research at Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
As of November 12, 2026, Find a Trial lists 4 clinical trials run by Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea that are recruiting, at sites in 2 countries (most in Spain (4), Portugal (1)). By phase: Phase 2 (3). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 4Clinical trials
- 2Countries
Newest trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Brentuximab Vedotin plus CHP as first-line therapy for CD30-positive peripheral T-cell lymphoma in Spain | — | A Coruña, A Coruña and 36 other locations | Recruiting | Jun 3, 2026 |
| Pirtobrutinib plus rituximab for adults with newly diagnosed indolent mantle cell lymphoma | Phase 2 | Lisbon, Lisbon District and 15 other locations | Recruiting | Dec 16, 2025 |
| Axicabtagene ciloleucel for adults with late-relapsing diffuse large B‑cell lymphoma | Phase 2 | A Coruña, A Coruña and 14 other locations | Recruiting | Nov 28, 2025 |
| Epcoritamab with response-adaptive escalation for first-relapse large B‑cell lymphoma | Phase 2 | Seville, Andalusia and 18 other locations | Recruiting | Aug 17, 2025 |
All recruiting trials (4)
-
Brentuximab Vedotin plus CHP as first-line therapy for CD30-positive peripheral T-cell lymphoma in Spain
This study looks at how safe and effective BV-CHP is when used as the first treatment for adults with CD30-positive peripheral T-cell lymphoma in real-world Spanish clinical care.
-
Pirtobrutinib plus rituximab for adults with newly diagnosed indolent mantle cell lymphoma
This trial will test whether combining pirtobrutinib with rituximab is effective and safe for adults newly diagnosed with indolent mantle cell lymphoma.
-
Axicabtagene ciloleucel for adults with late-relapsing diffuse large B‑cell lymphoma
This trial will try axicabtagene ciloleucel (a CD19 CAR‑T cell therapy) in adults with diffuse large B‑cell lymphoma who have a late relapse after initial treatment.
-
Epcoritamab with response-adaptive escalation for first-relapse large B‑cell lymphoma
This will try epcoritamab alone for three cycles and, for some patients, switch to epcoritamab plus tafasitamab and lenalidomide to see if it improves response in people with first-relapse large B‑cell lymphoma.
Quick answers
How many clinical trials run by Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea are recruiting right now?
4, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 2 countries. The most sites are in Spain (4 trials), Portugal (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 3. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.